Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase.

Disease models & mechanisms - 1 Sept 2011

Siller Saul S, Broadie Kendal

Abstract excerpt

Fragile X syndrome (FXS), caused by loss of the fragile X mental retardation 1 (FMR1) product (FMRP), is the most common cause of inherited intellectual disability and autism spectrum disorders. FXS patients suffer multiple behavioral symptoms, including hyperactivity, disrupted circadian cycles, and learning and memory deficits. Recently, a study in the mouse FXS model showed that the tetracycline derivative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Shape
Share to Circadian Clocks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Matrix Metalloproteinase 1

Share to Minocycline

Share to Mushroom Bodies

Share to Nerve Net

Share to Neuromuscular Junction

Share to Tissue Inhibitor of Metalloproteinases

Source

Open in PubMed Open full text

Identifiers

PMID: 21669931
DOI: 10.1242/dmm.008045
PMCID: PMC3180232

Genes

FMR1
MMP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase.PMID 21669931Read ↗

Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X SyndromeSemantic proximity Read ↗

High MMP‐9 activity levels in fragile X syndrome are lowered by minocyclineSemantic proximity Read ↗

Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.Semantic proximity Read ↗

A <i>Drosophila</i> screen of schizophrenia-related genes highlights the requirement of neural and glial matrix metalloproteinases for neuronal remodelingSemantic proximity Read ↗

Drosophila matrix metalloproteinases are required for tissue remodeling, but not embryonic development.Semantic proximity Read ↗

Defective neuronal development in the mushroom bodies of Drosophila fragile X mental retardation 1 mutants.Semantic proximity Read ↗

Matrix metalloproteinases promote motor axon fasciculation in the Drosophila embryo.Semantic proximity Read ↗

Drosophila MMP2 regulates the matrix molecule faulty attraction (Frac) to promote motor axon targeting in Drosophila.Semantic proximity Read ↗

Role of matrix metalloproteinase-9 in neurodevelopmental deficits and experience-dependent plasticity in Xenopus laevisSemantic proximity Read ↗

The extracellular metalloprotease AdamTS-A anchors neural lineages in place within and preserves the architecture of the central nervous system.Semantic proximity Read ↗

Role of matrix metalloproteinase-9 in neurodevelopmental disorders and experience-dependent plasticity in Xenopus tadpolesSemantic proximity Read ↗

Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.